TYRA

Tyra Biosciences is a drug development company working on treatments for cancer and genetic disorders. The company uses a technology platform called SNÅP to design medicines that target a specific protein called FGFR3, which plays a role in several diseases. Their main experimental drug is being tested in patients with bladder cancer and other tumors, while other candidates in development target rare bone disorders like achondroplasia and liver cancers. The company was founded in 2018 and is based in California.